CABA vs. ALEC, VALN, PROK, ALLO, HUMA, TSHA, FATE, CCCC, EDIT, and VYGR
Should you be buying Cabaletta Bio stock or one of its competitors? The main competitors of Cabaletta Bio include Alector (ALEC), Valneva (VALN), ProKidney (PROK), Allogene Therapeutics (ALLO), Humacyte (HUMA), Taysha Gene Therapies (TSHA), Fate Therapeutics (FATE), C4 Therapeutics (CCCC), Editas Medicine (EDIT), and Voyager Therapeutics (VYGR). These companies are all part of the "biological products, except diagnostic" industry.
Alector (NASDAQ:ALEC) and Cabaletta Bio (NASDAQ:CABA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, community ranking, profitability, earnings, dividends and risk.
Alector currently has a consensus target price of $14.00, suggesting a potential upside of 169.23%. Cabaletta Bio has a consensus target price of $34.33, suggesting a potential upside of 180.96%. Given Alector's stronger consensus rating and higher possible upside, analysts plainly believe Cabaletta Bio is more favorable than Alector.
Alector has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500. Comparatively, Cabaletta Bio has a beta of 2.52, indicating that its stock price is 152% more volatile than the S&P 500.
Cabaletta Bio has lower revenue, but higher earnings than Alector. Cabaletta Bio is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.
Alector received 71 more outperform votes than Cabaletta Bio when rated by MarketBeat users. However, 69.44% of users gave Cabaletta Bio an outperform vote while only 60.58% of users gave Alector an outperform vote.
Cabaletta Bio has a net margin of 0.00% compared to Cabaletta Bio's net margin of -134.34%. Alector's return on equity of -40.83% beat Cabaletta Bio's return on equity.
85.8% of Alector shares are held by institutional investors. 14.0% of Alector shares are held by company insiders. Comparatively, 9.9% of Cabaletta Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
In the previous week, Alector had 8 more articles in the media than Cabaletta Bio. MarketBeat recorded 10 mentions for Alector and 2 mentions for Cabaletta Bio. Alector's average media sentiment score of 0.80 beat Cabaletta Bio's score of 0.20 indicating that Cabaletta Bio is being referred to more favorably in the news media.
Summary
Cabaletta Bio beats Alector on 9 of the 17 factors compared between the two stocks.
Get Cabaletta Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for CABA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CABA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cabaletta Bio Competitors List
Related Companies and Tools
